BridgeMD
BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology
EU CTIS ID: 2025-523620-44-02
What this study is testing
In this study, we aim to investigate the cardiovascular side effects of immune checkpoint inhibitors.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients presented to the oncology teams of Semmelweis University and clinics in the country wishing to join the research
- Planned immune checkpoint inhibitor therapy
- At least 18 years of age
- Signing of the patient information sheet and consent form by the patient
- Accessible medical history
You likely can't join if
- Lack of informed consent form
- Age under 18
- Illiteracy
- Pregnancy and breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.